Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer’s Association International Conference®


July 17, 2017 6:00 am ET

Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of data at The Alzheimer’s Association
International Conference taking place in London, July 16–20, 2017.

“Alzheimer’s disease remains one of the most daunting medical issues of
our time –for individuals and their families, for the scientific and
medical communities, and for public health,” said Darryle Schoepp, vice
president, neuroscience discovery, Merck Research Laboratories. “Merck
has extensive research underway to develop novel medicines for
Alzheimer’s disease, and to improve understanding of the science and
impact of this devastating disease.”

Notable abstracts to be presented at The Alzheimer’s Association
International Conference

Saturday, July 15

  • First Evaluation of the Neurofibrillary Tangles Radioligand
    [18F]MK-6240 in AD Patients (Poster presentation, Abstract IC-P-177,
    12:15 p.m. – 1:30 p.m. BST)
  • In Vitro Binding Studies to Evaluate the NFT-Specificity of [3H]MK-6240
    and [3H]AV-1451 Binding in Subcortical Regions of Human AD
    Brain (Poster presentation, Abstract IC-P-207, 12:15 p.m. – 1:30 p.m.

Sunday, July 16

  • The Race to Diagnose: Disease Severity As a Factor of AD Diagnosis
    (Poster presentation, Abstract P1-565, 9:30 a.m. – 4:15 p.m. BST)
  • Episode of Care Among AD Patients Newly Diagnosed in Inpatient Setting
    in the U.S. Medicare Population (Poster presentation, Abstract P1-590,
    9:30 a.m. – 4:15 p.m. BST)
  • Systems Pharmacology Analysis of the Aβ Oligomer Response Following
    BACE1 Inhibition: Evidence for Second-Order Aβ42 Oligomerization
    (Poster presentation, Abstract P1-108, 9:30 a.m. – 4:15 p.m. BST)

Monday, July 17

  • Comparison of Healthcare Costs for AD Patients Diagnosed in Inpatient
    Versus Non-Inpatient Setting (Poster presentation, Abstract P2-558,
    9:30 a.m. – 4:15 p.m. BST)
  • Health Care Use Among Newly Diagnosed AD Patients in a U.S. Commercial
    Medicare Advantage Insurance Plan (Poster presentation, Abstract
    P2-557, 9:30 a.m. – 4:15 p.m. BST)
  • Resilience Mechanism of the Amyloid Precursor Protein (APP) Pathway
    Revealed By Systems Pharmacology Modeling Following β- and γ-Secretase
    Inhibition (Poster presentation, Abstract P2-066, 9:30 a.m. – 4:15
    p.m. BST)
  • Acute Administration of a BACE Inhibitor in Healthy Humans Results in
    a Significant Reduction of Aβ Oligomers in Cerebrospinal Fluid (Oral
    presentation, Abstract O2-09-01, 2:00 p.m. – 2:15 p.m. BST)

Tuesday, July 18

  • Phenotypic Screening for Novel Inhibitors of Tau Aggregation in Human
    iPSC-Derived Neurons (Poster presentation, P3-083, 9:30 a.m. – 4:15
    p.m. BST)
  • Real-World Administration of the AD Assessment Scale-Cognitive (Poster
    presentation, Abstract P3-253, 9:30 a.m. – 4:15 p.m. BST)

Wednesday, July 19

  • Health Care Use Among Newly Diagnosed AD Patients in a U.S. Database
    of Employer-Sponsored Medicare Supplement Insurance Plans (Poster
    presentation, Abstract P4-358, 9:30 a.m. – 4:15 p.m. BST)
  • An Analytic Method to Address the Non-Linearity Form of AD Modifying
    Model (Poster presentation, Abstract P4-204, 9:30 a.m. – 4:15 p.m. BST)
  • Potentiation of Tau Pathology By the ApoEε4 Dementia Risk Allele
    (Poster presentation, Abstract P4-111, 9:30 AM – 4:15 PM BST)

Thursday, July 20

  • Leveraging Medicare Claims to Characterize Diagnostic Pathways in AD
    (Oral presentation, Abstract O5-03-03, 12:15 p.m. – 12:30 p.m. BST)

For more information, including a list of abstract titles, please visit:

About Merck’s Commitment to Alzheimer’s Disease

For more than 10 years, Merck has been researching different ways to
treat Alzheimer’s disease. In addition to our dedicated internal
research efforts, we are driving innovation in collaboration with others
and leveraging the latest innovations in brain imaging technology in
order to help identify individuals in the early stages of Alzheimer’s
disease. Merck is working to improve our understanding of the disease to
help those living with Alzheimer’s and their loved ones around the world.

About Merck

For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
and connect with us on TwitterFacebookInstagram,
and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. There can be no guarantees with
respect to pipeline products that the products will receive the
necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2016 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (

Pamela Eisele, 267-305-3558
Ian McConnell, 973-901-5722
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Unsubscribe from email alerts